<bill session="110" type="hc" number="192" updated="2013-07-19T22:10:26-04:00">
  <state datetime="2007-07-25">REFERRED</state>
  <status>
    <introduced datetime="2007-07-25"/>
  </status>
  <introduced datetime="2007-07-25"/>
  <titles>
    <title as="introduced" type="official">Expressing the sense of Congress regarding the need for further study of the neurological disorder dysnia.</title>
  </titles>
  <sponsor id="400093"/>
  <cosponsors/>
  <actions>
    <action state="REFERRED" datetime="2007-07-25">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2007-07-25">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Committee on Energy and Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Access to health care"/>
    <term name="Economics and public finance"/>
    <term name="Education"/>
    <term name="Epidemiology"/>
    <term name="Federal aid to research"/>
    <term name="Health education"/>
    <term name="Higher education"/>
    <term name="Medical education"/>
    <term name="Medical research"/>
    <term name="Medical tests"/>
    <term name="Muscular diseases"/>
    <term name="Neurology"/>
    <term name="Science, technology, communications"/>
  </subjects>
  <amendments/>
  <summary>7/25/2007--Introduced.
Urges the Director of the National Institutes of Health (NIH) to take a leadership role in the fight against the neurological disorder dystonia. Calls for: (1) increased funding for basic biomedical research for dystonia and other neurological disorders through NIH; (2) additional research to identify an accurate diagnostic test for dystonia and an epidemiological study to determine the frequency of the disease; (3) improved patient access to safe and effective dystonia therapies; and (4) increased public awareness and professional education regarding dystonia through partnerships between the government and patient advocacy organizations.</summary>
</bill>
